Bioceres Crop Solutions Corp. (BIOX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a 17% revenue decline and competitive pricing pressures in key markets. Despite improved gross margins and EBITDA, weak sales in major regions and delayed product launches in Europe raise concerns. The Q&A session failed to clarify these issues, adding to uncertainties. Given these factors, a negative sentiment is justified.
Key Financial Performance
Gross Profit $36 million, remained almost equal year-over-year despite a drop in revenues, with a gross margin expansion of 650 basis points. This was due to the seed business model transition and a lower emphasis on opportunistic third-party product sales.
Total Revenues $77.5 million, a 17% decline year-over-year. The decline was due to the transition of the seed business to a more scalable and capital-efficient model, deprioritizing lower-margin sales, sales timing effects in Latin America, and uneven recovery in Argentina.
Crop Protection Revenues $39.9 million, a 16% decline year-over-year. The decline was due to sluggish demand in Argentina, tight credit conditions, uncertainty ahead of elections, and lower sales of bioprotection products in the U.S. and adjuvants in Brazil.
Seed and Integrated Products Revenues $12.6 million, a 37% decline year-over-year. The decline was due to the unwinding of the HB4 downstream program, which is expected to continue for at least two more quarters.
Crop Nutrition Revenues $25.1 million, broadly in line with last year, with a modest 2% year-over-year decline. Higher biostimulant sales in Argentina and Brazil were offset by weaker fertilizer dynamics and delayed purchases in Paraguay and Uruguay.
Adjusted EBITDA $13.6 million, a 61% increase year-over-year. The increase was driven by a $5.9 million reduction in operating costs, joint venture contributions, and gross margin expansion.
Gross Margin 47%, up from 40% year-over-year. The improvement was due to a better product mix and margin expansion across segments.
Crop Protection Gross Profit $17.6 million, a 5% decrease year-over-year, with gross margin improving from 39% to 44%. This was due to a favorable product mix and efficiency gains.
Seed and Integrated Products Gross Profit $7.5 million, slightly higher year-over-year despite lower revenue. Segment margin expanded from 36% to 60% due to the phasing out of low-margin seed sales and higher-margin seed treatment packs.
Crop Nutrition Gross Profit $11.1 million, a 6% decline year-over-year, with gross margin decreasing from 46% to 44%. The decline was due to competitive pricing in fertilizers in Argentina and changes in revenue composition under the Syngenta agreement.
Total Financial Debt $242.5 million as of September 30, 2026, down from $260.2 million in the previous quarter. The decrease was due to the repayment of working capital loans in Argentina.
Net Financial Debt $225.9 million, essentially flat versus the prior quarter. The net debt to adjusted EBITDA ratio improved to 6.8x.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Seed business model transition: Transitioning to a more scalable and capital-efficient model, deprioritizing lower-margin working capital-intensive sales.
HB4 downstream program: Unwinding of the program, leading to a temporary revenue decline in seeds but improving working capital and profitability.
Geographical performance: Sales timing effects in Latin America, particularly Uruguay, and uneven recovery in Argentina. Lower sales of bioprotection products in the U.S. and adjuvants in Brazil.
Gross margin expansion: Gross margin expanded significantly to 47% from 40% year-over-year, driven by improved product mix and efficiency gains.
SG&A cost reduction: Achieved 50% of the targeted $10-$12 million annualized savings in just one quarter.
Adjusted EBITDA: Increased by 61% to $13.6 million, reflecting improved operating performance and cost reductions.
Debt management: Reduced total financial debt to $242.5 million from $260.2 million, with a focus on liquidity and disciplined capital allocation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Total revenues for the quarter declined by 17% compared to the same period last year, driven by a transition in the seed business model and deprioritization of lower-margin sales. This decline is expected to continue for at least two more quarters, impacting financial performance.
Market Conditions in Argentina: Sluggish demand in Argentina due to tight credit conditions and uncertainty ahead of midterm elections slowed normalization of sales despite favorable weather and planting conditions.
Sales Timing Effects: Sales timing effects in Latin American countries, particularly Uruguay, and uneven recovery in Argentina negatively impacted revenues.
Debt Dispute: The company is undergoing a dispute with holders of secured convertible and nonconvertible notes, leading to reclassification of noncurrent debt as current and additional costs of $7.4 million related to the acceleration process. This creates financial uncertainty.
Competitive Pricing in Fertilizers: Margin compression in the Crop Nutrition segment was caused by competitive pricing in fertilizers in Argentina, where sales volumes increased but market prices declined.
Delayed Purchases in Paraguay and Uruguay: Delayed purchases in these regions offset gains in fertilizer demand, contributing to a modest 2% year-over-year decline in the Crop Nutrition segment.
Lower Sales in the U.S. and Brazil: Lower sales of bioprotection products in the U.S. and adjuvants in Brazil negatively impacted the Crop Protection segment, with sales expected to even out over the coming quarters.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company expects the revenue decline in seeds to continue for at least two more quarters as they compare against quarters where seed inventory was being sold off. This transition is expected to improve working capital and support a more profitable business model in the long term.
Market Trends and Recovery: Normalization in Argentina is expected to continue, albeit at a slower pace due to tight credit conditions and political uncertainty. Sales timing effects in Latin America, particularly Uruguay, are expected to even out over the coming quarters.
Profitability and Margins: The company is targeting profitability above 20% of adjusted EBITDA over sales, supported by gross margin expansion and cost reductions. They aim to achieve a $10 million to $12 million reduction in annual SG&A expenses, with 50% of the top range already achieved in the first quarter.
Segment Performance: In Crop Protection, lower sales in the U.S. and Brazil are expected to even out over the coming quarters. In Crop Nutrition, demand for micro-beaded fertilizers in Argentina is improving, supported by strong corn planting intentions, though delayed purchases in Paraguay and Uruguay may offset gains.
Debt and Liquidity: The company is actively managing liquidity and debt maturities, maintaining constructive dialogue with lenders, and prioritizing financial flexibility and disciplined capital allocation.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is there potential for raw crops or inputs like fertilizers and pesticides to be imported from Argentina into the U.S., and how would this impact demand for farmers or the company?
A:Federico Trucco noted that beef and milk production in Argentina are booming, with profitability at an all-time high. U.S. imports from Argentina are fortifying this process. Argentina's classification on the low tariff end benefits the company when serving the U.S. market with Argentine-manufactured agricultural input products. Additionally, the company has manufacturing capacity in the U.S., producing most of its bioprotection solutions domestically, which has been beneficial for addressing the U.S. market.
Q:How are the expected Corteva sales of biopesticides into Europe playing out relative to expectations?
A:Federico Trucco clarified that the company currently does not have bioprotection products registered in Europe. However, Corteva is a main customer for their biostimulant package in Europe. Historically, Europe has contributed significantly in the last quarter of each fiscal year, but this was not observed last quarter. Only marginal sales of biostimulants in Europe have been achieved in the current quarter. Most biostimulant improvements have been in Argentina and Latin America, and Corteva Europe sales are expected later in the year.
Q:Review of Unclear Management Responses
A:No questions were directly avoided, but the response regarding Corteva sales in Europe lacked clarity on specific timelines or detailed reasons for the delay in sales.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Argentina sale
Argentina segment
Argentina term
Bioceres Crop
Brazil fertilizer
Crop Nutrition
Crop Protection
Integrated Products
SGA improvement
Seed Integrated
Uruguay
bioprotection product
capital model
decline respect
decline revenue
decrease
fertilizer Argentina
gain
highlight
increase
margin expansion
margin seed
model transition
month
normalization
number margin
pack
planting
product adjuvant
product mix
quarter seed
recognition
respect margin
revenue decline
segment sale
sharing agreement
timing
volume
BIOX Transcript
Bioceres Crop Solutions Corp. (BIOX) Q3 2026 Earnings Call Transcript
Unknown5-12
The earnings call reveals significant financial challenges, including a 23% revenue decline, negative EBITDA, and high debt with liquidity concerns. Market conditions remain tough, with competitive pressures and inventory issues. The strategic shift has led to a sharp decline in Seeds revenue. Legal risks and uncertain outcomes add to the uncertainty. The Q&A session showed management's evasiveness on cash flow details, further raising concerns. Overall, these factors indicate a strong negative sentiment, likely leading to a stock price decline.
Bioceres Crop Solutions Corp. (BIOX) Q1 2026 Earnings Call Transcript
Unknown11-13
The earnings call highlights a 17% revenue decline and competitive pricing pressures in key markets. Despite improved gross margins and EBITDA, weak sales in major regions and delayed product launches in Europe raise concerns. The Q&A session failed to clarify these issues, adding to uncertainties. Given these factors, a negative sentiment is justified.
Bioceres Crop Solutions Corp. (BIOX) Q4 2025 Earnings Call Transcript
Unknown9-9
The earnings call presents mixed signals. Financial performance is weak, with negative EBITDA and reduced revenue, but there's optimism in cash flow and strategic initiatives like Rinotec approval and HB4 expansion. The Q&A highlights focus on cash generation and profitability, yet lacks clarity on HB4 and Syngenta revenue guidance. While cost savings and new partnerships are positive, the financial struggles and unclear guidance balance the sentiment, leading to a neutral prediction.
Bioceres Crop Solutions Corp. (BIOX) Q3 2025 Earnings Call Transcript
Unknown5-21
The earnings call highlights several challenges: a significant revenue decline, competitive pressures, and regulatory issues. Despite some positive aspects like improved cash flow and geographic diversification, the company's high leverage ratio and lack of shareholder returns are concerning. The Q&A section revealed uncertainties and vague responses from management, further adding to negative sentiment. While there are some positive developments, such as partnerships and market recovery signs, the overall tone remains negative due to financial struggles and market challenges, especially in Argentina.
BIOX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
